Logo
x

Search

Subscribe Now

J&J

Johnson & Johnson Reports P-III (MARIPOSA) Trial Data of Rybrevant + Lazcluze for EGFRm NSCLC

Johnson & Johnson Reports P-III (MARIPOSA) Trial Data of Rybrevant + Lazcluze for EGFRm NSCLC

  • March 27, 2025
Johnson & Johnson Reports the US FDA’s Approval of Subcutaneous & Intravenous Tremfya for Active Crohn’s Disease (CD)

Johnson & Johnson Reports the US FDA’s Approval of Subcutaneous & Intravenous Tremfya for Active Crohn’s Disease (CD)

  • March 21, 2025
Johnson & Johnson Highlights P-III Clinical Data of Icotrokinra for Plaque Psoriasis at AAD 2025

Johnson & Johnson Highlights P-III Clinical Data of Icotrokinra for Plaque Psoriasis at AAD 2025

  • March 10, 2025
Johnson & Johnson MedTech Launches Shockwave Javelin Peripheral IVL Catheter in the US

Johnson & Johnson MedTech Launches Shockwave Javelin Peripheral IVL Catheter in the US

  • March 6, 2025
The US FDA Approves sNDA for J&J’s Spravato (esketamine) to Treat Major Depressive Disorder (MDD)

The US FDA Approves sNDA for J&J’s Spravato (esketamine) to Treat Major Depressive Disorder (MDD)

  • January 22, 2025
Johnson & Johnson Submits NDA to the US FDA for TAR-200 to Treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC)

Johnson & Johnson Submits NDA to the US FDA for TAR-200 to Treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer (HR...

  • January 17, 2025
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.